Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The quest for an antibody-based HIV vaccine.

Literature DB >> 28133795

The quest for an antibody-based HIV vaccine.

Barton F Haynes¹, John R Mascola².

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2017 PMID： 28133795 PMCID： PMC5384259 DOI： 10.1111/imr.12517

Source DB: PubMed Journal: Immunol Rev ISSN： 0105-2896 Impact factor: 12.988

× No keyword cloud information.

59 in total

Review 1. Antibody polyspecificity and neutralization of HIV-1: a hypothesis.

Authors: Barton F Haynes; M Anthony Moody; Laurent Verkoczy; Garnett Kelsoe; S Munir Alam
Journal: Hum Antibodies Date: 2005

2. Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Authors: Barton F Haynes; Peter B Gilbert; M Juliana McElrath; Susan Zolla-Pazner; Georgia D Tomaras; S Munir Alam; David T Evans; David C Montefiori; Chitraporn Karnasuta; Ruengpueng Sutthent; Hua-Xin Liao; Anthony L DeVico; George K Lewis; Constance Williams; Abraham Pinter; Youyi Fong; Holly Janes; Allan DeCamp; Yunda Huang; Mangala Rao; Erik Billings; Nicos Karasavvas; Merlin L Robb; Viseth Ngauy; Mark S de Souza; Robert Paris; Guido Ferrari; Robert T Bailer; Kelly A Soderberg; Charla Andrews; Phillip W Berman; Nicole Frahm; Stephen C De Rosa; Michael D Alpert; Nicole L Yates; Xiaoying Shen; Richard A Koup; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Nelson L Michael; Jerome H Kim
Journal: N Engl J Med Date: 2012-04-05 Impact factor: 91.245

3. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.

Authors: Glenda E Gray; Mary Allen; Zoe Moodie; Gavin Churchyard; Linda-Gail Bekker; Maphoshane Nchabeleng; Koleka Mlisana; Barbara Metch; Guy de Bruyn; Mary H Latka; Surita Roux; Matsontso Mathebula; Nivashnee Naicker; Constance Ducar; Donald K Carter; Adrien Puren; Niles Eaton; M Julie McElrath; Michael Robertson; Lawrence Corey; James G Kublin
Journal: Lancet Infect Dis Date: 2011-05-11 Impact factor: 25.071

4. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

Authors: Barton F Haynes; Judith Fleming; E William St Clair; Herman Katinger; Gabriela Stiegler; Renate Kunert; James Robinson; Richard M Scearce; Kelly Plonk; Herman F Staats; Thomas L Ortel; Hua-Xin Liao; S Munir Alam
Journal: Science Date: 2005-04-28 Impact factor: 47.728

5. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors: Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal: J Infect Dis Date: 2006-11-03 Impact factor: 5.226

6. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine.

Authors: Peter Gilbert; Maggie Wang; Terri Wrin; Chris Petropoulos; Marc Gurwith; Faruk Sinangil; Patricia D'Souza; Isaac R Rodriguez-Chavez; Allan DeCamp; Mike Giganti; Phillip W Berman; Steve G Self; David C Montefiori
Journal: J Infect Dis Date: 2010-08-15 Impact factor: 5.226

7. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Authors: Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim
Journal: N Engl J Med Date: 2009-10-20 Impact factor: 91.245

8. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Authors: Susan P Buchbinder; Devan V Mehrotra; Ann Duerr; Daniel W Fitzgerald; Robin Mogg; David Li; Peter B Gilbert; Javier R Lama; Michael Marmor; Carlos Del Rio; M Juliana McElrath; Danilo R Casimiro; Keith M Gottesdiener; Jeffrey A Chodakewitz; Lawrence Corey; Michael N Robertson
Journal: Lancet Date: 2008-11-13 Impact factor: 79.321

9. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study.

Authors: Barton F Haynes; Garnett Kelsoe; Stephen C Harrison; Thomas B Kepler
Journal: Nat Biotechnol Date: 2012-05-07 Impact factor: 54.908

10. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens.

Authors: Xiaodong Xiao; Weizao Chen; Yang Feng; Zhongyu Zhu; Ponraj Prabakaran; Yanping Wang; Mei-Yun Zhang; Nancy S Longo; Dimiter S Dimitrov
Journal: Biochem Biophys Res Commun Date: 2009-09-11 Impact factor: 3.575

60 in total

1. Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses.

Authors: Mohammad Mohseni Sajadi; Amir Dashti; Zahra Rikhtegaran Tehrani; William D Tolbert; Michael S Seaman; Xin Ouyang; Neelakshi Gohain; Marzena Pazgier; Dongkyoon Kim; Guy Cavet; Jean Yared; Robert R Redfield; George K Lewis; Anthony L DeVico
Journal: Cell Date: 2018-05-03 Impact factor: 41.582

2. SOS and IP Modifications Predominantly Affect the Yield but Not Other Properties of SOSIP.664 HIV-1 Env Glycoprotein Trimers.

Authors: Rajesh P Ringe; Philippe Colin; Jonathan L Torres; Anila Yasmeen; Wen-Hsin Lee; Albert Cupo; Andrew B Ward; P J Klasse; John P Moore
Journal: J Virol Date: 2019-12-12 Impact factor: 5.103

3. Enhancing humoral immunity via sustained-release implantable microneedle patch vaccination.

Authors: Archana V Boopathy; Anasuya Mandal; Daniel W Kulp; Sergey Menis; Nitasha R Bennett; Hannah C Watkins; Wade Wang; Jacob T Martin; Nikki T Thai; Yanpu He; William R Schief; Paula T Hammond; Darrell J Irvine
Journal: Proc Natl Acad Sci U S A Date: 2019-07-29 Impact factor: 11.205

4. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.

Authors: Benedikt Asbach; Karen V Kibler; Josef Köstler; Beatriz Perdiguero; Nicole L Yates; Sherry Stanfield-Oakley; Georgia D Tomaras; Shing-Fen Kao; Kathryn E Foulds; Mario Roederer; Michael S Seaman; David C Montefiori; Robert Parks; Guido Ferrari; Donald N Forthal; Sanjay Phogat; James Tartaglia; Susan W Barnett; Steven G Self; Raphael Gottardo; Anthony D Cristillo; Deborah E Weiss; Lindsey Galmin; Song Ding; Jonathan L Heeney; Mariano Esteban; Bertram L Jacobs; Giuseppe Pantaleo; Ralf Wagner
Journal: J Virol Date: 2019-01-17 Impact factor: 5.103

Review 5. Targeting the N332-supersite of the HIV-1 envelope for vaccine design.

Authors: Thandeka Moyo; Dale Kitchin; Penny L Moore
Journal: Expert Opin Ther Targets Date: 2020-04-27 Impact factor: 6.902

Review 6. Glycosylation profiling to evaluate glycoprotein immunogens against HIV-1.

Authors: Anna-Janina Behrens; Weston B Struwe; Max Crispin
Journal: Expert Rev Proteomics Date: 2017-09-14 Impact factor: 3.940

7. Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses.

Authors: Ann J Hessell; Rebecca Powell; Xunqing Jiang; Christina Luo; Svenja Weiss; Vincent Dussupt; Vincenza Itri; Alisa Fox; Mariya B Shapiro; Shilpi Pandey; Tracy Cheever; Deborah H Fuller; Byung Park; Shelly J Krebs; Maxim Totrov; Nancy L Haigwood; Xiang-Peng Kong; Susan Zolla-Pazner
Journal: Cell Rep Date: 2019-07-23 Impact factor: 9.423

8. Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles.

Authors: Mariane Melo; Ely Porter; Yuan Zhang; Murillo Silva; Na Li; Brian Dobosh; Alessia Liguori; Pat Skog; Elise Landais; Sergey Menis; Devin Sok; David Nemazee; William R Schief; Ron Weiss; Darrell J Irvine
Journal: Mol Ther Date: 2019-08-19 Impact factor: 11.454

9. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques.

Authors: Ling Xu; Amarendra Pegu; Ercole Rao; Nicole Doria-Rose; Jochen Beninga; Krisha McKee; Dana M Lord; Ronnie R Wei; Gejing Deng; Mark Louder; Stephen D Schmidt; Zachary Mankoff; Lan Wu; Mangaiarkarasi Asokan; Christian Beil; Christian Lange; Wulf Dirk Leuschner; Jochen Kruip; Rebecca Sendak; Young Do Kwon; Tongqing Zhou; Xuejun Chen; Robert T Bailer; Keyun Wang; Misook Choe; Lawrence J Tartaglia; Dan H Barouch; Sijy O'Dell; John-Paul Todd; Dennis R Burton; Mario Roederer; Mark Connors; Richard A Koup; Peter D Kwong; Zhi-Yong Yang; John R Mascola; Gary J Nabel
Journal: Science Date: 2017-09-20 Impact factor: 47.728

10. Functional Optimization of Broadly Neutralizing HIV-1 Antibody 10E8 by Promotion of Membrane Interactions.

Authors: Edurne Rujas; Daniel P Leaman; Sara Insausti; Lei Ortigosa-Pascual; Lei Zhang; Michael B Zwick; José L Nieva
Journal: J Virol Date: 2018-03-28 Impact factor: 5.103